Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2025 06:30 ET | Source: Fortrea Holdings Inc

Fortrea Reports Second Quarter 2025 Results

For the three months ended June 30, 2025, from continuing operations: Revenues of $710.3 millionGAAP net loss of $(374.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA of...
August 05, 2025 18:00 ET | Source: Fortrea Holdings Inc

Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations

DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice...
August 04, 2025 16:30 ET | Source: Fortrea Holdings Inc

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it issued grants of employment...
July 16, 2025 07:00 ET | Source: Fortrea Holdings Inc

Fortrea Announces Date for Second Quarter 2025 Financial Results and Conference Call

DURHAM, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter...
June 24, 2025 10:33 ET | Source: Fortrea Holdings Inc

Fortrea และ Emery Pharma ประกาศความร่วมมือเชิงกลยุทธ์เพื่อดำเนินการศึกษาวิจัยอันตรกิริยาระหว่างยาที่สอดคล้องกับ FDA โดยใช้ยาไรแฟมปิน (Rifampin)

เดอร์แฮม, รัฐนอร์ทแคโรไลนา, June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (“บริษัท”) ซึ่งเป็นองค์กรวิจัยตามสัญญา (Contract Research Organization, CRO) ทางคลินิกชั้นนำระดับโลก...
June 24, 2025 10:33 ET | Source: Fortrea Holdings Inc

Fortrea y Emery Pharma anuncian colaboración estratégica para realizar estudios de interacción fármaco-fármaco que cumplan con la FDA utilizando rifampicina

DURHAM, Carolina del Norte, June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (la "Empresa"), una organización líder mundial en investigación por contrato (CRO), anunció hoy una colaboración...
June 24, 2025 10:33 ET | Source: Fortrea Holdings Inc

Fortrea dan Emery Pharma Umumkan Kerjasama Strategik untuk Menjalankan Kajian Interaksi Ubat yang Mematuhi Piawaian FDA Menggunakan Rifampin

DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (“Syarikat”), sebuah organisasi penyelidikan kontrak (CRO) global terkemuka, hari ini mengumumkan kerjasama strategik dengan...
June 24, 2025 10:33 ET | Source: Fortrea Holdings Inc

Fortrea ו-Emery Pharma מכריזות על שיתוף פעולה אסטרטגי לביצוע מחקרי אינטראקציה בין תרופות באמצעות ריפמפיצין, בהתאם לתקני ה-FDA

דורהאם, קרוליינה הצפונית, June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (נאסד"ק:FTRE) ("החברה"), חברה שהיא ארגון מחקר מבוסס חוזים (CRO) גלובלית מובילה, הודיעה היום על שיתוף פעולה אסטרטגי עם Emery...
June 24, 2025 10:33 ET | Source: Fortrea Holdings Inc

Fortrea und Emery Pharma kündigen strategische Zusammenarbeit zur Durchführung FDA-konformer Arzneimittelwechselwirkungsstudien mit Rifampin an

Durham, North Carolina, June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (das „Unternehmen“), ein führendes globales Auftragsforschungsinstitut (Contract Research Organization CRO), hat...
June 24, 2025 10:33 ET | Source: Fortrea Holdings Inc

Fortrea et Emery Pharma annoncent une collaboration stratégique visant à mener des études sur les interactions médicamenteuses répondant aux normes de la FDA en utilisant la rifampicine

DURHAM, Caroline du Nord, 24 juin 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq : FTRE) (la « Société »), une société de recherche contractuelle d’envergure mondiale (CRO) de premier plan, a annoncé...